ABL Diagnostics (Euronext Paris:ABLD), a provider of molecular biology tests, announced on Friday that it has filed a bid to acquire the business operations and assets of IntegraGen, a company specialising in genomic analysis of nucleic acids, particularly in oncology and rare genetic diseases.
The bid was filed on 11 September under Article L.642-1 of the French Commercial Code as IntegraGen undergoes judicial reorganisation proceedings before the Commercial Court of Évry. The proposed acquisition aligns with ABL Diagnostics' growth strategy and its evaluation of external growth opportunities that complement its existing portfolio.
The transaction remains subject to a decision by the Commercial Court of Évry, and ABL Diagnostics said there is no assurance it will be selected as the successful bidder.
Akeso presents positive results from registrational Phase III study of ivonescimab
US FDA grants orphan drug designation for Lundbeck's asedebart
ABL Diagnostics files bid to acquire IntegraGen
ABEC opens new manufacturing facility in Wilson, NC
Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock
Insilico Medicine doses first patient in Phase III trial of rentosertib
Tyra Biosciences declares positive Phase 2 results for oral dabogratinib in bladder cancer
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Altesa BioSciences presents positive vapendavir clinical data at ERS International Congress 2026
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer